FDA Approves New Animal Drug Application for GMO Salmon

Last week, the Food and Drug Administration approved a supplemental New Animal Drug Application (NADA) submitted by AquaBounty Technologies, Inc. While the original application was approved in 2015, this current application grants AquaBounty Technologies, Inc. the right to raise a GMO salmon species it has developed called AquAdvantage salmon at their farming facility near Albany, Indiana. The facility uses growth tanks rather than ocean pens and will be able to grow 1,200 tons of GMO salmon per year. The facility was designed so it can be expanded quickly to meet higher levels of demand for the new product. As soon as the FDA and Department of Agriculture agree on guidelines for consumer labeling of the genetically engineered AquAdvantage salmon, the company will be allowed to import the genetically modified eggs from their facilities in Canada and Panama, where the company currently genetically engineers its eggs. The eggs will then be grown and sold in the U.S. market.…

Read more detail on Recent Admiralty Law posts –

This entry was posted in Admiralty-Maritime Law and tagged , , , , . Bookmark the permalink.

Leave a Reply